References

rpcardio

Rational Pharmacotherapy in Cardiology

Рациональная Фармакотерапия в Кардиологии

1819-64462225-3653

«SILICEA-POLIGRAF» LLC

10.20996/1819-6446-2021-12-11

rpcardio-2636

Research Article

ELECTRONIC PAGES

ЭЛЕКТРОННЫЕ СТРАНИЦЫ

Drug-Induced Atrial Fibrillation / Atrial Flutter

Лекарственно-индуцированная фибрилляция/трепетание предсердий

https://orcid.org/0000-0002-0795-8225

Остроумова

О. Д.

Ostroumova

O. D

Остроумова Ольга Дмитриевна.

Москва.

eLibrary SPIN 3910-6585

Olga D. Ostroumova.

Moscow.

eLibrary SPIN 3910-6585

https://orcid.org/0000-0003-3091-7904

Черняева

М. С.

Chernyaeva

M. S.

Черняева Марина Сергеевна.

Москва.

eLibrary SPIN 2244-0320

Marina S. Cherniaeva.

Moscow.

eLibrary SPIN 2244-0320

doctor@cherniaeva.ru

https://orcid.org/0000-0001-5801-3742

Кочетков

А. И.

Kochetkov

A. I.

Кочетков Алексей Иванович.

Москва.

eLibrary SPIN 9212-6010

Aleksey I. Kochetkov.

Moscow.

eLibrary SPIN 9212-6010

https://orcid.org/0000-0003-1183-4716

Воробьева

А. Е.

Vorobieva

A. E.

Воробьева Анастасия Евгеньевна.

Москва.

eLibrary SPIN 8579-3163

Anastasiya E. Vorobyova.

Moscow.

eLibrary SPIN 8579-3163

https://orcid.org/0000-0003-4434-9311

Бахтеева

Д. И.

Bakhteeva

D. I.

Бахтеева Дамиря Исхаковна.

Москва.

eLibrary SPIN 3664-5299

Damiry I. Bakhteeva.

Moscow.

eLibrary SPIN 3664-5299

https://orcid.org/0000-0001-5581-8182

Корчагина

С. П.

Korchagina

S. P.

Корчагина Стелла Павловна.

Москва.

eLibrary SPIN 4006-4669

Stella P. Korchagina.

Moscow.

eLibrary SPIN 4006-4669

Бондарец

О. В.

Bondarets

O. V.

Бондарец Ольга Валентиновна.

Москва.

eLibrary SPIN 7785-0655

Olga V. Bondarec.

Moscow.

eLibrary SPIN 7785-0655

https://orcid.org/0000-0002-9463-392X

Бойко

Н. Д.

Boyko

N. D.

Бойко Наталья Дмитриевна.

Москва.

eLibrary SPIN 5018-1458

Natalya D. Boyko.

Moscow.

eLibrary SPIN 5018-1458

https://orcid.org/0000-0002-4496-3680

Сычев

Д. А.

Sychev

D. A.

Сычев Дмитрий Алексеевич.

Москва.

eLibrary SPIN 4525-7556

Dmitry A. Sychev.

Moscow.

eLibrary SPIN 4525-7556

Российская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuing Professional EducationRussian Federation

Центральная государственная медицинская академия Управления делами Президента; Госпиталь для ветеранов войн № 2РоссияCentral State Medical Academy of the Administrative Department of the President; Hospital for War Veterans No. 2Russian Federation

Московский государственный медико-стоматологический университет имени А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovaRussian Federation

Госпиталь для ветеранов войн № 2РоссияHospital for War Veterans No. 2Russian Federation

Медицинский центр MedSwissРоссияMedSwiss Medical CenterRussian Federation

2021

12012022

176

e1-e18

2022

Остроумова О.Д., Черняева М.С., Кочетков А.И., Воробьева А.Е., Бахтеева Д.И., Корчагина С.П., Бондарец О.В., Бойко Н.Д., Сычев Д.А.

Ostroumova O.D., Chernyaeva M.S., Kochetkov A.I., Vorobieva A.E., Bakhteeva D.I., Korchagina S.P., Bondarets O.V., Boyko N.D., Sychev D.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rpcardio.online/jour/article/view/2636

Drug-induced atrial fibrillation / flutter (DIAF) is a serious and potentially life-threatening complication of pharmacotherapy. Purpose of the work: systematization and analysis of scientific literature data on drugs, the use of which can cause the development of DIAF, as well as on epidemiology, pathophysiological mechanisms, risk factors, clinical picture, diagnosis and differential diagnosis, treatment and prevention of DIAF. Analysis of the literature has shown that many groups of drugs can cause the development of DIAF, with a greater frequency while taking anticancer drugs, drugs for the treatment of the cardiovascular, bronchopulmonary and central nervous systems. The mechanisms and main risk factors for the development of DIAF have not been finally established and are known only for certain drugs, therefore, this section requires further study. The main symptoms of DIAF are due to the severity of tachycardia and their influence on the parameters of central hemodynamics. For diagnosis, it is necessary to conduct an electrocardiogram (ECG) and Holter monitoring of an ECG and echocardiography. Differential diagnosis should be made with AF, which may be caused by other causes, as well as other rhythm and conduction disturbances. Successful treatment of DIAF is based on the principle of rapid recognition and immediate discontinuation of drugs (if possible), the use of which potentially caused the development of adverse drug reactions (ADR). The choice of management strategy: heart rate control or rhythm control, as well as the method of achievement (medication or non-medication), depends on the specific clinical situation. For the prevention of DIAF, it is necessary to instruct patients about possible symptoms and recommend self-monitoring of the pulse. It is important for practitioners to be wary of the risk of DIAF due to the variety of drugs that can potentially cause this ADR.

Лекарственно-индуцированная фибрилляция/трепетание предсердий (ЛИФП/ТП) представляет собой серьезное и потенциально угрожающее жизни осложнение фармакотерапии. Цель работы: систематизация и анализ данных научной литературы о лекарственных средствах (ЛС), применение которых может вызвать развитие ЛИФП/ТП, а также об эпидемиологии, патофизиологических механизмах, факторах риска, клинической картине, диагностике и дифференциальной диагностике, лечении и профилактике ЛИФП/ТП. Анализ литературы показал, что многие группы ЛС могут вызывать развитие ЛИФП/ТП, с большей частотой – на фоне приема противоопухолевых ЛС, ЛС для лечения сердечно-сосудистой, бронхолегочной и центральной нервной систем. Механизмы и основные факторы риска развития ЛИФП/ТП окончательно не установлены и известны лишь для отдельных ЛС, поэтому данный раздел требует дальнейшего изучения. Основные симптомы ЛИФП/ТП обусловлены выраженностью тахикардии и их влиянием на параметры центральной гемодинамики. Для диагностики необходимо проведение электрокардиограммы (ЭКГ) и холтеровского мониторирования ЭКГ и эхокардиографии. Дифференциальный диагноз следует проводить с ФП/ТП, которые могут быть вызваны иными причинами, а также с другими нарушениями ритма и проводимости. Успешное лечение ЛИФП/ТП базируется на принципе быстрого распознавания и немедленной отмены ЛС (если это возможно), применение которого потенциально явилось причиной развития нежелательных лекарственных реакций (НЛР). Выбор стратегии ведения: контроль частоты сердечных сокращений или контроль ритма, а также способ достижения (медикаментозно или немедикаментозно) зависит от конкретной клинической ситуации. Для профилактики ЛИФП/ТП необходимо проинструктировать пациентов о возможных симптомах и рекомендовать самоконтроль пульса. Практикующим врачам важно иметь настороженность в отношении риска возникновения ЛИФП/ТП ввиду многообразия ЛС, которые потенциально могут стать причиной развития данной НЛР.

лекарственно-индуцированная фибрилляция предсердийнежелательные лекарственные реакциипротивоопухолевые лекарственные средствабисфосфонатыглюкокортикоидынестероидные противовоспалительные средстваиммунодепрессантыместные анестетикианаболические стероидыникотин

drug-induced atrial fibrillationadverse drug reactionsanticancer drugsbisphosphonatesglucocorticoidsnonsteroidal anti-inflammatory drugsimmunosuppressantslocal anestheticsanabolic steroidsnicotine

References1

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/europace/euw295.

Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52. DOI:10.1161/01.cir.98.10.946.

Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The Am J Med. 2002;113(5):359-64. DOI:10.1016/s0002-9343(02)01236-6.

Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case control study. Eur Heart J. 2013;34(14):1061-7. DOI:10.1093/eurheartj/ehs469.

Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8. DOI:10.1161/STROKEAHA.113.00232.

Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.

Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.00511.

Wolf PA, Abbott R, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8. DOI:10.1161/01.str.22.8.983.

Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242-6. DOI:10.1016/s0735-1097(00)00982-7.

Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Medю 2004;140(4):265-8. DOI:10.7326/0003-4819-140-4-200402170-00008.

Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 г.» [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf].

Atrial fibrillation and flutter. Clinical guidelines (2020) [cited 2021 Jul 30]. Available from: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf (In Russ.)

Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I (K, A Ch) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697-706. DOI:10.1161/CIRCULATIONAHA.105.575332.

Van Wagoner DR, Pond AL, Lamorgese M, et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85(5):428-36. DOI:10.1161/01.res.85.5.428.

van der Hooft CS, Heeringa J, van HG, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44(11):2117-24. DOI:10.1016/j.jacc.2004.08.053

Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018

Остроумова О.Д., Черняева М.С., Комарова А.Г., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с приемом сердечно-сосудистых лекарственных средств. Сибирское Медицинское Обозрение. 2020;(6):5-13. DOI:10.20333/2500136-2020-6-5-13.

Ostroumova OD, Chernyaeva MS, Komarova AG, et al. Drug-induced atrial fibrillation associated with the intake of cardiovascular drugs. Siberian Medical Review. 2020;(6):5-13. (In Russ.) DOI:10.20333/2500136-2020-6-5-13.

Tamargo J, Caballero R, Delpón E. Drug-induced atrial fibrillation: does it matter? Discovery Medicine. 2012;14(78):295-9.

Остроумова О.Д., Черняева М.С., Масленникова О.М., и др. Лекарственно-индуцированная фибрилляция/трепетание предсердий, ассоциированная с приемом лекарственных средств, влияющих на центральную нервную систему. Фарматека. 2021;(3):10-7. DOI:10.18565/pharmateca.

Ostroumova OD, Chernyaeva MS, Maslennikova OM, et al. Drug-induced atrial fibrillation / flutter associated with the use of drugs that affect the central nervous system. Pharmateca. 2021;(3):10-7 (In Russ.) DOI:10.18565/pharmateca.

Остроумова О.Д., Черняева М.С., Кочетков А.И., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с применением противоопухолевых лекарственных средств. Безопасность и Риск Фармакотерапии. 2020;8(4):178-90. DOI:10.30895/2312-7821-2020-8-4-178-190.

Ostroumova OD, Chernyaeva MS, Kochetkov AI, et al. Drug-induced atrial fibrillation associated with the use of anticancer drugs. Safety and Risk of Pharmacotherapy. 2020;8(4):178-90. (In Russ.) DOI:10.30895/2312-7821-2020-8-4-178-190.

Остроумова О.Д., Черняева М.С., Бахтеева Д.И., и др. Отдельные группы лекарственных средств, прием которых ассоциирован с развитием лекарственно-индуцированной фибрилляции предсердий. Медицинский Алфавит. 2021;1(11):20-8. DOI:10.33667/2078-5631-2021-11-20-28.

Ostroumova OD, Cherniaeva MS, Bakhteeva DI, et al. Some groups of drugs which use is associated with development of drug-induced atrial fibrillation. Medical Alphabet. 2021;1(11):20-28. (In Russ.) DOI:10.33667/2078-5631-2021-11-20-28.

Strickberger SA, Man KC, Daoud EG. Adenosine-induced Atrial Arrhythmia: A Prospective Analysis. Ann Intern Med. 1997;127(6):417-22. DOI:10.7326/0003-4819-127-6-199709150-00001

Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99(8):1034-40. DOI:10.1161/01.cir.99.8.1034.

Camaiti A, Pieralli F, Olivotto I, et al. Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur J Emerg Med. 2001;8(2):99-105 DOI:10.1097/00063110-200106000-00005.

Belhassen B, Pelleg A, Shoshani D. Atrial Fibrillation Induced by Adenosine Triphosphate. Am J Cardiol. 1984;53(9):1405-6. DOI:10.1016/0002-9149(84)90104-8.

Garratt CJ, Antoniou A, Griffith MJ, Ward DE. Use of Intravenous Adenosine in Sinus Rhythm as a Diagnostic Test for Latent Preexcitation. Am J Cardiol. 1990;65(13):868-73. DOI:10.1016/0002-9149(90)91428-9.

Meurer MK. A 21-year-old Woman With Rapid Atrial Fibrillation After Adenosine Administration. J Emerg Nurs. 1991;17(3):135-6.

Cowell RP, Paul VE, Ilsley CD. Haemodynamic Deterioration After Treatment With Adenosine. Br Heart J. 1994;71(6):569-71. DOI:10.1136/hrt.71.6.569.

Crosson JE, Etheridge SP, Milstein S. Therapeutic and Diagnostic Utility of Adenosine During Tachycardia Evaluation in Children. Am J Cardiol. 1994;74(2):155-60. DOI:10.1016/0002-9149(94)90089-2.

Tebbenjohanns J, Pfeiffer D, Schumacher B, et al. Intravenous Adenosine During Atrioventricular Reentrant Tachycardia: Induction of Atrial Fibrillation With Rapid Conduction Over an Accessory Pathway. Pacing Clin Electrophysiol. 1995;18(4):743-6. DOI:10.1111/j.1540-8159.1995.tb04673.x.

Silverman AJ, Machado C, Baga JJ, et al. Adenosine-induced Atrial Fibrillation. Am J Emerg Med. 1996;14(3):300-1. DOI:10.1016/S0735-6757(96)90182-5.

Kaplan IV, Kaplan AV, Fisher JD. Adenosine Induced Atrial Fibrillation Precipitating Polymorphic Ventricular Tachycardia. Pacing Clin Electrophysiol. 2000;23(1):140-1. DOI:10.1111/j.1540-8159.2000.tb00662.x

Israel C, Klingenheben T, Grönefeld G. Adenosine-induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2000;11(7):825. DOI:10.1111/j.1540-8167.2000.tb00057.x.

Jonathan RK, Ronn ET, Maully JSh, et al. Induction of Atrial Fibrillation After the Routine Use of Adenosine. Pediatr Emerg Care. 2006;22(2):113-5. DOI:10.1097/01.pec.0000199558.88733.49.

Matthew C, Jaffar R, Assad M. Atrial Fibrillation During Adenosine Pharmacologic Stress Testing. J Nucl Cardiol. 2006;13(4):576-81. DOI:10.1016/j.nuclcard.2006.05.006.

Stuber T, Lim PB, O'Neill MD, Peters NS. Ultra Rapid Local Activity in Adenosine-Induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2008;19(5):566-7. DOI:10.1111/j.1540-8167.2007.01044.x.

Kanei Y, Hanon S, Van-Tosh A, Schweitzer P. Adenosine-induced Atrial Fibrillation During Pharmacologic Stress Testing: Report of Eight Cases and Review of the Literature. Int J Cardiol. 2008;129(1):e15-7. DOI:10.1016/j.ijcard.2007.05.090.

Turley AJ, Murray S, Thambyrajah J. Pre-excited Atrial Fibrillation Triggered by Intravenous Adenosine: A Commonly Used Drug With Potentially Life-Threatening Adverse Effects. Emerg Med J. 2008;25(1):46-8. DOI:10.1136/emj.2007.051227.

Park E, Price A, Vidovich MI. Adenosine-induced Atrial Fibrillation During Fractional Flow Reserve Measurement. Cardiol J. 2012;19(6):650-1. DOI:10.5603/cj.2012.0121.

Walter JHJr, Patricia ETh, Christopher SS. Induction of Atrial Fibrillation With Adenosine During a Transesophageal Electrophysiology Study to Risk Stratify a Patient With Asymptomatic Ventricular Preexcitation. Congenit Heart Dis. 2013;8(4):E99-E101. DOI:10.1111/j.1747-0803.2012.00682.x.

Salaria V, Mehta NJ, Abdul-Aziz S, et al. Role of postoperative use of adrenergic drugs in occurrence of atrial fibrillation after cardiac surgery. Clin Cardiol. 2005;28(3):131-5. DOI:10.1002/clc.4960280306.

Kane GC, Hepinstall MJ, Kidd GM, et al. Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr. 2008;21(4):337-41. DOI:10.1016/j.echo.2007.08.028.

Carasso S, Sandach A, Kuperstein R, et al. Atrial fibrillation in dobutamine stress echocardiography. Int J Cardiol. 2006;111(1):53-8. DOI:10.1016/j.ijcard.2005.07.001.

Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients. Circulation. 1993;88:15-9. DOI:10.1161/01.cir.88.1.15.

Secknus MA, Marwick TH. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol. 1997;29(6):1234-40. DOI:10.1016/s0735-1097(97)00039-9.

Feneck RO, Sherry KM, Withington PS, et al. Comparison of the Hemodynamic Effects of Milrinone With Dobutamine in Patients After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2001;15(3):30615. DOI:10.1053/jcan.2001.23274.

Baig MW, Sheard K, Thorley PJ, et al. The Use of Dobutamine Stress Thallium Scintigraphy in the Diagnosis of Syndrome X. Postgrad Med J. 1992;68 Suppl 2:S20-4.

Poldermans D, Fioretti PM, Boersma E. et al. Safety of Dobutamine-Atropine Stress Echocardiography in Patients With Suspected or Proven Coronary Artery Disease. Am J Cardiol. 1994;73(7):456-9. DOI:10.1016/0002-9149(94)90675-0.

Wirtz CE. Sustained Atrial Fibrillation After Dobutamine Stress Echocardiography in an Older Patient With Left Atrial Enlargement. West J Med. 1995;162(3):268-9.

Cornel JH, Balk AH, Boersma E, et al. Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. J Am Soc Echocardiogr. 1996;9(1):27-32. DOI:10.1016/s0894-7317(96)90101-7.

Yeo TC, Ng WL, Ling LH, et al. Dobutamine stress echocardiography in the elderly Asian patients. Ann Acad Med Singap. 1997;26(2):165-7.

Pezzano A, Gentile F, Mantero A, et al. [RITED (RegistroItaliano Test Eco-Dobutamina): side effects and complications of echo-dobutamine stress test in 3041 examinations]. Giornaleitaliano di Cardiologia. 1998;28(2):102-11 (In Italian).

Elhendy A, van Domburg RT, Bax JJ, et al. Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly. Chest. 2000;117(3):649-56. DOI:10.1378/chest.117.3.649.

Coisne D, Donal E, Torremocha F, et al. Dobutamine stress echocardiography response of asymptomatic patients with diabetes. Echocardiography. 2001;18(5):373-9. DOI:10.1046/j.1540-8175.2001.00373.x.

Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dipyridamole stress echocardiography in hypertensive patients. J Hypertens. 2002;20(7):1423-9. DOI:10.1097/00004872-200207000-00030.

Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 2004;25(14):1230-6. DOI:10.1016/j.ehj.2003.11.018.

Onorati F, Renzulli A, De Feo M, et al. Perioperative enoximone infusion improves cardiac enzyme release after CABG. J Cardiothorac Vasc Anesth. 2004;18(4):409-14 DOI:10.1053/j.jvca.2004.05.016.

Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91. DOI:10.1001/jama.297.17.1883.

Sheldon SH, Askew JW 3rd, Klarich KW, et al. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr. 2011;24(1):86-90. DOI:10.1016/j.echo.2010.10.008.

Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of newonset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33(6):1327-32. DOI:10.1097/01.ccm.0000166876.41694.ca.

Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7. DOI:10.1001/jama.287.12.1541.

Wright EM, Sherry KM. Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth. 1991;67(5):585-90. DOI:10.1093/bja/67.5.585.

Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth. 1992;6(5):563-7. DOI:10.1016/1053-0770(92)90098-r.

Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118(16):1619-25. DOI:10.1161/CIRCULATIONAHA.108.790162.

Smith AH, Owen J, Borgman KY, et al. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol. 2011;108(11):1620-4. DOI:10.1016/j.amjcard.2011.07.023.

Acharya D, Sanam K, Revilla-Martinez M, et al. Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. Am J Cardiol. 2016;117(6):952-6. DOI:10.1016/j.amj-card.2015.12.030.

Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol. 1999;10(9):1180-7. DOI:10.1111/j.1540-8167.1999.tb00293.x.

Donald HSc, Melissa SD. Paroxysmal Atrial Fibrillation Precipitated by Amiodarone-Induced Thyrotoxicosis Five Months After Cessation of Therapy. J Emerg Med. 2006;31(1):61-4. DOI:10.1016/j.jemermed.2005.08.011.

Ibrahim HK, Talat Y, Bulent MK. Atrial Fibrillation Due to Late Amiodarone-Induced Thyrotoxicosis. Clin Drug Investig. 2008;28(8):527-31. DOI:10.2165/00044011-200828080-00008.

Остроумова О.Д., Качан В.О., Кочетков А.И., Краснов Г.С. Лекарственно-индуцированный гипотиреоз. Фарматека. 2020;27(3):107-17. DOI:10.18565/pharmateca.2020.3.107-117.

Ostroumova OD, Kachan VO, Kochetkov AI, Krasnov GS. Drug-induced hypothyroidism. Pharmateca. 2020;27(3):107-17 (In Russ.) DOI:10.18565/pharmateca.2020.3.107-117.

Гайсёнок О.В. Нарушения сердечного ритма в реальной врачебной практике: амиодарон-индуцированный тиреотоксикоз 2-го типа как причина рецидивирующей фибрилляции предсердий. Рациональная Фармакотерапия в Кардиологии. 2010;6(4):518-21. DOI:10.20996/1819-6446-2010-6-4-518-521.

Gaisenok OV. Сardiac arrhythmias in medical practice: clinical case of amiodarone-induced thyrotoxicosis type 2 as a cause of recurrent atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2010;6(4):518-21 (In Russ.) DOI:10.20996/1819-6446-2010-6-4-518-521.

Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter Ablation of Atrial Flutter Due to Amiodarone Therapy for Paroxysmal Atrial Fibrillation. Eur Heart J. 2000;21(7):565-72. DOI:10.1053/euhj.1999.1865.

Kaakeh Y, Overholser BR, Lopshire JC, Tisdale E. Drug-Induced Atrial Fibrillation. Drugs. 2012;72(12):1617-30. DOI:10.2165/11633140-000000000-00000.

Tamargo J, Delpon E, Caballero R. The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf. 2006;5(3):453-67. DOI:10.1517/14740338.5.3.453.

Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation. 2000;102(20):2503-8. DOI:10.1161/01.cir.102.20.2503.

Digitalis Investigation Group. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New Engl J Med. 1997;336(8):525-33. DOI:10.1056/NEJM199702203360801.

Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8. DOI:10.1001/jama.289.7.871.

Мареев В.Ю., Фомин И.В., Агеев Ф.Т, и др. Клинические рекомендации ОССН-РКО-РНМОТ. сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI:10.18087/cardio.2475.

Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.) DOI:10.18087/cardio.2475.

Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart. 2001;85(4):424-9. DOI:10.1136/heart.85.4.424.

Murdock CJ. Atrial Flutter in Patients Treated for Atrial Fibrillation With Propafenone. Am J Cardiol. 1990;66(7):755-7. DOI:10.1016/0002-9149(90)91144-u.

Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol. 1990;66(3):378-83. DOI:10.1016/0002-9149(90)90856-v.

Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angéiol (Paris). 2003;52(1):34-40. DOI:10.1016/s0003-3928(02)00183-x.

Shenasa M, Kus T, Fromer M, et al. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol. 1988;62(7):403-7. DOI:10.1016/0002-9149(88)90967-8.

Doiuchi J, Hamada M, Ochi T, et al. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy. Clin Cardiol. 1985;8(3):176-9. DOI:10.1002/clc.4960080311.

Isomoto S, Shimizu A, Knoe A, et al. Effects of intravenous verapamil on atrial vulnerability. Jpn Circ J. 1994;58(1):1-8. DOI:10.1253/jcj.58.1.

Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82(8A):10N-17N. DOI:10.1016/s0002-9149(98)00735-8.

Falk RH, Knowlton AA, Manaker S. Verapamil-induced Atrial Fibrillation. N Engl J Med. 1988;318(10):640-1. DOI:10.1056/NEJM198803103181014.

Garratt C, Linker N, Griffith M, et al. Comparison of Adenosine and Verapamil for Termination of Paroxysmal Junctional Tachycardia. Am J Cardiol. 1989;64(19):1310-6. DOI:10.1016/0002-9149(89)90573-0.

Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. BJOG. 2006;113(7):844-5. DOI:10.1111/j.1471-0528.2006.00964.x.

Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. DOI:10.1016/S0140-6736(10)61198-1.

Fox K, Ford I, Gabriel Ph, et al. Jean-Claude Tardif, Michal Tendera, Roberto Ferrari, SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9. DOI:10.1056/NEJMoa1406430.

Fox K, Ford I, Gabriel Ph, et al. Bradycardia and Atrial Fibrillation in Patients With Stable Coronary Artery Disease Treated With Ivabradine: An Analysis From the SIGNIFY Study. Eur Heart J. 2015;36(46):3291-6. DOI:10.1093/eurheartj/ehv451.

Cammarano C, Silva M, Comee M, et al. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Clini Ther. 2016;38(2):387-95. DOI:10.1016/j.clinthera.2015.12.018.

Mengesha HG, Weldearegawi B, Petrucka P, et al. Effect of Ivabradine on Cardiovascular Outcomes in Patients With Stable Angina: Meta-Analysis of Randomized Clinical Trials. BMC Cardiovasc Disord. 2017;17(1):105. DOI:10.1186/s12872-017-0540-3.

Martin RI, Pogoryelova O. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506-10. DOI:10.1136/heartjnl-2014-305482.

Tanboğa İH, Topçu S, Aksakal E, et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Metaanalysis With Trial Sequential Analysis of More Than 40000 Patients. Clin Cardiol. 2016;39(10):615-20. DOI:10.1002/clc.22578.

Emara MK, Saadet AM. Transient atrial fibrillation in hypertensive patients with thiazide induced hypokalaemia. Postgrad Med J. 1986;62(734):1125-7. DOI:10.1136/pgmj.62.734.1125.

Zhang N, Chen K, Zhao J, et al. Another Side Effect of Ticagrelor: Atrial Fibrillation. Int J Cardiol. 2016;212:242-4. DOI:10.1016/j.ijcard.2016.03.091.

McCune KH, O’Brien CJ. Atrial fibrillation induced by ibuprofen overdose. Postgrad Med J. 1993;69(810):325-6. DOI:10.1136/pgmj.69.810.325-a.

100

Vasheghani-Farahani A, Sahraian MA, Darabi L, et al. Incidence of Various Cardiac Arrhythmias and Conduction Disturbances Due to High Dose Intravenous Methylprednisolone in Patients With Multiple Sclerosis. J Neurol Sci. 2011;309(1-2):75-8. DOI:10.1016/j.jns.2011.07.018.

101

McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest. 1993;104(2):622-3. DOI:10.1378/chest.104.2.622.

102

Moretti R, Torre P, Antonello RM, et al Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol. 2000;7(1):130. DOI:10.1046/j.1468-1331.2000.00026.x.

103

Ueda N, Yoshikawa T, Chihara M, et al. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol. 1988;2(1):29-31. DOI:10.1007/BF00870376.

104

Yamamura K, Ohga S, Nishiyama K, et al. Recurrent atrial fibrillation after high-dose methylprednisolone therapy in a girl with lupus-associated hemophagocytic syndrome. Lupus 2011;20(8):871-5. DOI:10.1177/0961203310392429.

105

Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther. 2001;8(4):303–5. DOI:10.1097/00045391-200107000-00013.

106

Dogukan A, Ilkay E, Poyrazoglu OK, et al. Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferative glomerulonephritis. Acta Medica (Hradec Kralove). 2008;51(1):63-4. DOI:10.14712/18059694.2017.34.

107

Iqbal FM, Beeharilal PS, Sadat K, et al. Steroid induced atrial fibrillation. Compr Ther. 2008;34(2):111–4.

108

van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20. DOI:10.1001/archinte.166.9.1016.

109

De CR, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.

110

Oteri A, Bussolini A, Sacchi M, et al. A case of atrial fibrillation induced by inhaled fluticasone propionate. Pediatrics. 2010;126(5):e1237-41. DOI:10.1542/peds.2010-0419.

111

De Caterina R, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.

112

Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. DOI:10.1136/bmj.d3450.

113

Merli GJ, Weitz H, Martin JH, et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med. 1986;146(1):45-7.

114

Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol. 1999;83(8):1186-90. DOI:10.1016/s0002-9149(99)00057-0.

115

Sueda S, Fukuda H, Watanabe K, et al. Clinical characteristics and possible mechanism of paroxysmal atrial fibrillation induced by intracoronary injection of acetylcholine. Am J Cardiol. 2001;88(5):570-3. DOI:10.1016/s0002-9149(01)01744-1.

116

Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. J Clin Psychopharmacol. 1998;18(2):170. DOI:10.1097/00004714-199804000-00010.

117

Shaibani A, Fares S, Selam, et al. Lacosamide in painful diabetic neuropathy: an 18-week double blind placebo controlled trial. J Pain. 2009;10(8):818-28. DOI:10.1016/j.jpain.2009.01.322.

118

De Giorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322-4. DOI:10.1016/j.yebeh.2010.04.043.

119

Lee CW, Muo CH, Liang JA, et al. Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. Medicine (Baltimore). 2016;95(11):e3102. DOI:10.1097/MD.0000000000003102.

120

Peacock WF, Hollander JE, Diercks DB, et al. Morphine and Outcomes in Acute Decompensated Heart Failure: An ADHERE Analysis. Emerg Med J. 2008;25(4):205-9. DOI:10.1136/emj.2007.050419.

121

Sabzi F, Zokaei AH, Moloudi AR. Predictors of atrial fibrillation following coronary artery bypass grafting. Clin Med Insights Cardiol. 2011;5:67-75. DOI:10.4137/CMC.S7170.

122

Waters BM, Joshi KG, Flynn J. Olanzapine-Associated New-Onset Atrial Fibrillation. J Clin Psychopharmacol. 2008;28(3):354-5. DOI:10.1097/JCP.0b013e318173082c.

123

Davis LE, Becher MW, Tlomak W, et al. Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology. Am J Psychiatry. 2005;162(1):28-33. DOI:10.1176/appi.ajp.162.1.28.

124

Yaylaci S, Tamer A, Kocayigit I, Gunduz H. Atrıal fıbrıllatıon due to olanzapine overdose. Clin Toxicol (Phila). 2011;49(5):440. DOI:10.3109/15563650.2011.588605.

125

Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anaesth. 2003;50(3):229-31. DOI:10.1007/BF03017789.

126

Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009;43(3):532-6. DOI:10.1345/aph.1L544.

127

Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am J Health Syst Pharm. 2008;65(22):2122-5. DOI:10.2146/ajhp070615.

128

Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ. 2000;321(7256):275. DOI:10.1136/bmj.321.7256.275.

129

Devadathan S, Gunning M. Atrial fibrillation following oral sumatriptan administration. Int J Cardiol. 2006;107(1):112-3. DOI:10.1016/j.ijcard.2004.11.039.

130

White WB, Wong SH. Rapid atrial fibrillation associated with trazodone hydrochloride. Arch Gen Psychiatry. 1985;42(4):424. DOI:10.1001/archpsyc.1985.01790270114017.

131

Qureshi WT, O’Neal WT, Khodneva Y, et al. Association between opioid use and atrial fibrillation: the reasons for geographic and racial differences in stroke (REGARDS) study. JAMA Intern Med. 2015;175(6):1058-60. DOI:10.1001/jamainternmed.2015.1045.

132

Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry. 1991;52(4):174-6.

133

Roberge RJ, Martin G. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994;23(3):586-90. DOI:10.1016/s0196-0644(94)70083-4.

134

Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205-13. DOI:10.1200/JCO.2002.20.1.205.

135

Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104(3):655-8. DOI:10.1182/blood-2003-07-2345.

136

Gridelli C, Cigolari S, Gallo C, et al. MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(2-3):277-84. DOI:10.1016/s0169-5002(00)00194-x.

137

Tavil Y, Arslan U, Okyay K, et al. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man. Onkologie. 2007;30(5):253-5. DOI:10.1159/000100930.

138

Santini D, Tonini G, Abbate A, et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol. 2000;11(4):479-81. DOI:10.1023/a:1008380208045.

139

Ciotti R, Belotti G, Facchi E, et al. Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999;10(8):997. DOI:10.1023/a:1008305716918.

140

Ferrari D, Carbone C, Codeca C, et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs. 2006;17(3):359-61. DOI:10.1097/00001813-200603000-00016.

141

Numico G, Castiglione F, Granetto C, et al. Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35(1):59-64. DOI:10.1016/s0169-5002(01)00269-0.

142

Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100(3):262-5. DOI:10.1097/01.smj.0000257382.89910.fe.

143

Dindogru A, Barcos M, Henderson ES, Wallace HJJr. Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol. 1978;5(1):65-71. DOI:10.1002/mpo.2950050110

144

Oster MW, Rakowski TJ. Myocardial injury immediately following adriamycin administration. Med Pediatr Oncol. 1981;9(5):463-5. DOI:10.1002/mpo.2950090508.

145

Montella L, Caraglia M, Addeo R, et al. Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert’s disease). Ann Hematol. 2005;84(3):192-3. DOI:10.1007/s00277-004-0867-6.

146

Palma M, Mancuso A, Grifalchi F. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002;88(6):527-9.

147

Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. DOI:10.1182/blood-2016-05-712828.

148

Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31-37.e13. DOI:10.1016/j.clml.2016. 09.010.

149

Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One 2019;14(2):e0211228. DOI:10.1371/journal.pone.0211228.

150

Емелина Е.И., Гендлин Г.Е., Никитин И.Г., и др. Нарушения ритма и проводимости у пациентов, получающих лечение ибрутинибом. Клиническая Онкогематология. 2019;12(2):220-30. DOI:10.21320/2500-2139-2019-12-2-220-230.

Emelina EI, Gendlin GE, Nikitin IG, et al. Rhythm and conduction disturbances in patients treated with ibrutinib. Clinical Hematology Oncology. 2019;12(2):220-30 (In Russ.) DOI:10.21320/2500-2139-2019-12-2-220-230.

151

Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–9. DOI:10.1080/10428194.2016.1257795.

152

Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7(1):7-20. DOI:10.1200/JCO.1989.7.1.7.

153

Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997;3(3):157-62.

154

Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7(4):486-98. DOI:10.1200/JCO.1989.7.4.486.

155

Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31-6. DOI:10.7326/0003-4819-118-1-199301010-00006.

156

Illiano A, Barletta E, De Marino V, et al. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res. 2000;20(5C):3999–4003.

157

Pérez PE, Mesa MG, García SPJ, González RAP. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther. 2011;28 Suppl 1:11-6. DOI:10.1007/s12325-010-0102-x.

158

Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant. 1998;21(10):1049-53. DOI:10.1038/sj.bmt.1701217.

159

Moreau P, Milpied N, Mahé B, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23(10):1003-6. DOI:10.1038/sj.bmt.1701763.

160

Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10(7):473-83. DOI:10.1016/j.bbmt.2004.03.001.

161

Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356-9. DOI:10.1002/clc.20904.

162

Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25(5):533-9. DOI:10.1038/sj.bmt.1702188.

163

Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stern cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575-9. DOI:10.1080/1042819050023588.

164

Zingler VC, Nabauer M, Jahn K. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol. 2005;54(1):28-33. DOI:10.1159/000087242.

165

Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2003;95(10):977-81.

166

Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004;90(3):285-8.

167

Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;(15):117-30.

168

Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579-86. DOI:10.1093/europace/eup300.

169

Moscetti L, Ramponi S, Maccaglia C, et al. Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy. Clin Ter. 1998;149(5):377-9.

170

Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-24. DOI:10.1200/JCO.2000.18.2.317.

171

Mego M, Reckova M, Obertova J, et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007;18(11):1906-7. DOI:10.1093/annonc/mdm489.

172

Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-37. DOI:10.1093/jnci/djk154.

173

Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007;13(2):211-2. DOI:10.1111/j.1524-4741.2007.00408.x.

174

Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-92. DOI:10.1038/sj.bjc.6604909.

175

Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91-8.

176

Yang X, Li X, Yuan M, et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018;9:1058. DOI:10.3389/fphar.2018.01058.

177

Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol). 1998;10(6):377-8. DOI:10.1016/s0936-6555(98)80033-2.

178

Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol. 2005;35(5):265-70. DOI:10.1093/jjco/hyi071.

179

Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24(7):1072-8. DOI:10.1200/JCO.2004.00.1792.

180

Ifran A, Kaptan K, Beyan C. High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am J Hematol. 2005;80(3):247. DOI:10.1002/ajh.20441.

181

Bischiniotis TS, Lafaras CT, Platogiannis DN, et al. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol. 2005;46(5):324-9.

182

Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol. 1988;13(1):41-6. DOI:10.1016/0167-8140(88)90296-4.

183

Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol. 1991;9(1):192-3. DOI:10.1200/JCO.1991.9.1.192.

184

Tomkowski WZ, Wiśniewska J, Szturmowicz M, et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer. 2004;12(1):53-7. DOI:10.1007/s00520-003-0533-x.

185

Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405-11. DOI:10.1016/j.jtcvs.2009.02.046.

186

Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24(10):1561-7. DOI:10.1200/JCO.2005.04.6813.

187

Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostinecytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453-8. DOI:10.1016/j.jtcvs.2008.07.055.

188

Patel AK, Skatrud JB, Thomsen JH. Cardiac Arrhythmias Due to Oral Aminophylline in Patients With Chronic Obstructive Pulmonary Disease. Chest. 1981;80(6):661-5. DOI:10.1378/chest.80. 6.661.

189

Varriale P, Ramaprasad S. Aminophylline Induced Atrial Fibrillation. Pacing Clin Electrophysiol. 1993;16(10):1953-5. DOI:10.1111/j.1540-8159.1993.tb00987.x.

190

Chazan R, Karwat K, Tyminska K, et al. Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction. Int J Clin Pharmacol Ther. 1995;33(3):170-5.

191

Henderson A, Wright DM, Pond SM. Management of Theophylline Overdose Patients in the Intensive Care Unit. Anaesth Intensive Care. 1992;20(1):56-62. DOI:10.1177/0310057X9202000111.

192

Okada S, Teramoto S, Matsuoka R. Recovery From Theophylline Toxicity by Continuous Hemodialysis With Filtratio. Ann Intern Med. 2000;133(11):922. DOI:10.7326/0003-4819-133-11-200012050-00024.

193

Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M. Theophylline and Salbutamol in Combination in Patients With Obstructive Pulmonary Disease and Concurrent Heart Disease: Effect on Cardiac Arrhythmias. J Intern Med. 1989;226(4):229-34. DOI:10.1111/j.1365-2796.1989.tb01385.x.

194

Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987;82(4A):115-8.

195

Holden R. Probable fatal interaction between ciprofloxacin and theophylline. BMJ. 1988;297(6659):1339. DOI:10.1136/bmj.297.6659.1339.

196

Richardson JP. Theophylline Toxicity Associated With the Administration of Ciprofloxacin in a Nursing Home Patient. J Am Geriatr Soc. 1990;38(3):236-8. DOI:10.1111/j.1532-5415.1990.tb03497.x.

197

O' Driscoll BR. Supraventricular tachycardia caused by nebulized ipratropium bromide. Thorax. 1989;44(4):312. DOI:10.1136/thx.44.4.312.

198

Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007;3(2):56-60. DOI:10.1007/BF03160909.

199

MacMahon JR. Atrial fibrillation and sympathomimetics (letter). J Pediatr. 1974;84(4):613. DOI:10.1016/s0022-3476(74)80701-8.

200

Patane S, Marte F, La Rosa FC, La Rocca R. Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse. Int J Cardiol. 2010;145(2):e74-6. DOI:10.1016/j.ijcard.2008.12.159.

201

Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008;87(6):319-28. DOI:10.1097/MD.0b013e31818fcc02.

202

Michele J, Stephan FL, Wentworth C 3rd, et al. Comparative Safety of Long-Acting Inhaled Bronchodilators: A Cohort Study Using the UK THIN Primary Care Database. Drug Saf. 2007;30(12):1151-60. DOI:10.2165/00002018-200730120-00007.

203

Veloso HH, de Paola AAV. Atrial fibrillation after vardenafil therapy. Emerg Med J. 2005;22(11):823. DOI:10.1136/emj.2004.015982.

204

Frederiksen MC, Toig RM, Depp R. III. Atrial fibrillation during hexoprenaline therapy for premature labor. Am J Obstet Gynecol. 1983;145(1):108-9. DOI:1016/0002-9378(83)90350-2.

205

Varkey S. Overdose of yohimbine. BMJ. 1992;304(6826):548. DOI:10.1136/bmj.304.6826.548-a.

206

Hayashi K, Minezaki KK, Narukawa M, et al. Atrial fibrillation and continuous 161. hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn Heart J. 1999;40(6):827-30. DOI:10.1536/jhj.40.827.

207

Awan GM, Calderon E, Dawood G, Alpert MA. Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2000;320(1):69-71. DOI:10.1097/00000441-200007000-00011.

208

Cassinotti A, Massari A, Ferrara E., et al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol. 2007;63(9):875-8. DOI:10.1007/s00228-007-0328-y.

209

Riccioni G, Bucciarelli V, Di Ilio E, et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol. 2011;24(1):247-9. DOI:10.1177/039463201102400131.

210

Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed). 1985;291(6497):706. DOI:10.1136/bmj.291.6497.706.

211

Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000;72(12):517-19.

212

Paolicelli D, Manni A, Direnzo V, et al. Long-term Cardiac Safety and Tolerability of Fingolimod in Multiple Sclerosis: A Postmarketing Study. J Clin Pharmacol. 2015;55(10):1131-6. DOI:10.1002/jcph.519.

213

Rolf L, Muris A, Damoiseaux J, et al. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Neurology 2014;82(11):1008-9. DOI:10.1212/WNL.0000000000000218.

214

Wallemacq PE, Lesne ML. Accidental massive IV administration of cyclosporine in man. Drug Intell Clin Pharm, 1985;19(1):29-30. DOI:10.1177/106002808501900106.

215

LoVecchio FA, Goltz HR. Atrial fibrillation following acute overdose with oral cyclosporine. Ann Pharmacother. 2000;34(3):405. DOI:10.1345/aph.19134.

216

Pratila MG, Pratilas V. Dysrhythmia occurring during epidural anesthesia with bupivacaine. The Mt Sinai J Med. 1982;49(2):130-2.

217

Heckbert S, Guo L, Steven RC, et al. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008;168(8):826-31. DOI:10.1001/archinte.168.8.826.

218

Grosso A, Douglas I, Hingorani A. Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis. PLoS One. 2009;4(3):e4720. DOI:10.1371/journal.pone.0004720.

219

Herrera L, Leal I, Lapi F, et al. Risk of Atrial Fibrillation Among Bisphosphonate Users: A Multicenter, Population-Based, Italian Study. Osteoporosis Int. 2015;26(5):1499-506. DOI:10.1007/s00198-014-3020-y.

220

Black DM, Reiss TF, Nevitt MC, et al. Design of the Fracture Intervention Trial. Osteoporosis Int. 1993;3(3):S29-S39. DOI:10.1007/BF01623005.

221

Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-22. DOI:10.1056/NEJMoa067312.

222

Konsta M, Bournia VK, Dania V, Iliopoulos A. Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis. J Clin Rheumatol. 2014;20(4):239-40. DOI:10.1097/RHU.0000000000000114.

223

Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007;117(2):e86-7. DOI:10.1016/j.ijcard.2006.11.199.

224

Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851-7. DOI:10.1016/s0736-4679(99)00095-5.

225

Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005;81(3):578-82. DOI:10.1093/ajcn/81.3.578.

226

Choragudi NL, Aronow WS, DeLuca AJ. Nicotine gum-induced atrial fibrillation. Heart Dis. 2003;5(2):100-1. DOI:1010.1097/01.hdx.0000061700.11321.1a.

227

Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J. 1985;54(2):222-3. DOI:10.1136/hrt.54.2.222.

228

Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986;255(8):1018.

229

Craig TJ, Samuel LW, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. DOI:10.1016/j.jacc.2014.03.022.

230

Smeets JL, Allessie MA, Lammers WJ, et al. The Wavelength of the Cardiac Impulse and Reentrant Arrhythmias in Isolated Rabbit Atrium. The Role of Heart Rate, Autonomic Transmitters, Temperature, and Potassium. Circ Res. 1986;58(1):96-108. DOI:10.1161/01.res.58.1.96.

231

Rensma PL, Allessie MA, Lammers WJ, et al. Length of Excitation Wave and Susceptibility to Reentrant Atrial Arrhythmias in Normal Conscious Dogs. Circ Res. 1988;62(2):395-410. DOI:10.1161/01.res.62.2.395.

232

Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955-68. DOI:10.1172/JCI46315.

233

Ogawa M, Zhou S, Tan AY, et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007;50(4):335-43. DOI:10.1016/j.jacc.2007.03.045.

234

Chen PS, Douglas P. Zipes Lecture. Neural mechanisms of atrial fibrillation. Heart Rhythm. 2006;3(11):1373-7. DOI:10.1016/j.hrthm.2006.08.010.

235

Zhou S, Chang CM, Wu TJ, et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol. 2002;283(3):H1244–H1252. DOI:10.1152/ajpheart.01109.2001.

236

Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale based combined treatments against cancer. Cell Death Differ. 2014;21(1):1525. DOI:10.1038/cdd.2013.67.

237

Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945-53. DOI:10.1016/j.jacc.2013.11.026.

238

Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73. DOI:10.1161/CIRCEP.107.754564.

239

Hove-Madsen L, Llach A, Bayes-Genis A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110(11):1358-63. DOI:10.1161/01.CIR.0000141296.59876.87.

240

Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005;111(16):2025-32. DOI:10.1161/01.CIR.0000162461.67140.4C.

241

Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940-51. DOI:10.1172/jci37059.

242

Neef S, Dybkova N, Sossalla S, et al. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106(6): 1134-44. DOI:10.1161/CIRCRESAHA.109.203836.

243

Dobrev D, Voigt N, Wehrens X H. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2011;89(4):734-43. DOI:10.1093/cvr/cvq324.

244

Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145-56. DOI:10.1161/CIRCULATIONAHA.113.006641.

245

Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059-70. DOI:10.1161/CIRCULATIONAHA.111.067306.

246

Xing Y, Gao Y, Chen J, et al. Wenxin-Keli regulates the calcium/calmodulin-dependent protein kinase ii signal transduction pathway and inhibits cardiac arrhythmia in rats with myocardial infarction. Evid Based Complement Alternat Med. 2013;2013:464508. DOI:10.1155/2013/464508.

247

Yang X, Yu C, Li Y, et al. Effects of Wenxin Keli on cardiac hypertrophy and arrhythmia via regulation of the calcium/calmodulin dependent kinase ii signaling pathway. BioMed Res Int. 2017;2017:1569235. DOI:10.1155/2017/1569235.

248

Sag CM, Köhler AC, Anderson ME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51(5):749-59. DOI:10.1016/j.yjmcc.2011.07.016.

249

Давтян К.В., Калемберг А.А., Царева Е.Н., и др. Роль воспалительной теории в патогенезе фибрилляции предсердий. Российский Кардиологический Журнал 2019;24(7):110-4. DOI:10.15829/1560-4071-2019-7-110-114.

Davtyan KV, Kalemberg AA, Tsareva EN, et al. The role of the inflammatory theory in the pathogenesis of atrial fibrillation. Russian Journal of Cardiology. 2019;24(7):110-4 (In Russ.) DOI:10.15829/1560-4071-2019-7-110-114.

250

Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol. 2007;120(2):193-7. DOI:10.1016/j.ijcard.2006.09.015.

251

Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004;148(3):462-6. DOI:10.1016/j.ahj.2004.01.026.

252

Guzzetti S, Costantino G, Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation. 2002;106(9):e40. DOI:10.1161/01.cir.0000028399.42411.13.

253

Wang ZX, Wang HQ, Cheng J, et al. Research progress on pathogenesis of atrial fibrillation. China Medical Herald. 2018;15;26-9.

254

Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25. DOI:10.1093/jnci/djp44.

255

Liu Y, Tan D, Shi L, et al. Blueberry anthocyaninsenriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS ONE. 2015 2;10(7):e0127813. DOI:10.1371/journal.pone.0127813.

256

Gu JF. The research progress on cardiac toxic mechanism of anthracyclines and prevention treatment measures. World Notes Antibiot. 2015;6:241-8. DOI:10.13461/j.cnki.wna.004903.

257

Yang X, Li Y, Li Y, et al. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front Physiol. 2017;8:600. DOI:10.3389/fphys.2017.00600.

258

O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115(8):1090-4. DOI:10.1016/j.amjcard.2015.01.540.

259

Samman TA, Sandesara PB, Hayek SS, et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017;14(12):1849-55. DOI:10.1016/j.hrthm.2017.07.028.

260

Beck MA. Selenium and host defence towards viruses. Proc Nutr Soc. 1999;58(3):707-11. DOI:10.1017/s0029665199000920.

261

Ozaki M, Deshpande SS, Angkeow P, et al. Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J. 2000;14(2):418-29. DOI:10.1096/fasebj.14.2.418.

262

Keefe DL Anthracyciine-Induced cardiomyopathy. Seminars in oncology 2001;28(4 suppl 12):2-7. DOI:10.1053/sonc.2001.26431.

263

Gen W, Tani M, Takeshita J, et al. Mechanisms of Ca2+ overioad induced by extracellular H2O2 in quiescent isoiated rat cardiomyocytes. Basic Res Cardiol. 2001;96(6):623-9. DOI:10.1007/s003950170014.

264

Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. DOI:10.1161/CIR.0000000000000905.

265

Breeden CC, Safirstein BH. Spacer-induced Atrial Fibrillation. N J Med. 1990;87(2):113-4.

266

Сычев Д.А., Остроумова О.Д., Переверзев А.П., и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;27(6):113-26. DOI:10.18565/pharmateca.2020.6.113-126.

Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Pharmateca. 2020;27(6):113-26 (In Russ.) DOI:10.18565/pharmateca.2020.6.113-126.

267

Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter. Pharmacotherapy. 1997;17(6):1238-45.

268

Minton NA, Henry JA. Treatment of Theophylline Overdose. Am J Emerg Med. 1996;14(6):606-12. DOI:10.1016/S0735-6757(96)90111-4.

269

Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756-63. DOI:10.1093/eurheartj/ehy453.

270

Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. DOI:10.1093/europace/euab065.

271

Sychev D, Mirzaev K, Cherniaeva M, et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020;35(3). DOI:10.1515/dmpt-2020-0127.

The authors declare that there are no conflicts of interest present.